The Centers for Medicare and Medicaid Service’s proposal to allow Medicare to pay for amyloid-directed monoclonal antibody drugs for Alzheimer’s only when they are used in randomized controlled clinical trials could significantly curtail access to the drugs for at least four years, according to John Dwyer, president of the Global Alzheimer’s Platform Foundation and co-founder of UsAgainstAlzheimer’s.
Dwyer discussed the practical challenges posed by the coverage with evidence development requirement in the Medicare draft national coverage determination...